HBIO Logo

Harvard Bioscience, Inc. (HBIO) 

NASDAQ
Market Cap
$98.14M
Sector
Healthcare
Industry
Medical—Instruments & Supplies
Rank in Sector
310 of 963
Rank in Industry
19 of 49

Largest Insider Buys in Sector

HBIO Stock Price History Chart

HBIO Stock Performance

About Harvard Bioscience, Inc.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Insider Activity of Harvard Bioscience, Inc.

Over the last 12 months, insiders at Harvard Bioscience, Inc. have bought $90,500 and sold $0 worth of Harvard Bioscience, Inc. stock.

On average, over the past 5 years, insiders at Harvard Bioscience, Inc. have bought $222,280 and sold $1.16M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Green James W (Chief Executive Officer) — $181,000.

The last purchase of 10,000 shares for transaction amount of $29,100 was made by Green James W (Chief Executive Officer) on 2024‑06‑13.

List of Insider Buy and Sell Transactions, Harvard Bioscience, Inc.

2024-06-13PurchaseChief Executive Officer
10,000
0.0242%
$2.91$29,100-6.70%
2024-06-06PurchaseChief Executive Officer
20,000
0.0474%
$3.07$61,400-7.72%
2023-08-17PurchaseChief Executive Officer
25,000
0.06%
$4.38$109,500-1.39%
2023-03-15PurchaseChief Executive Officer
20,000
0.0468%
$2.60$52,000+71.21%
2023-03-15Purchasedirector
16,192
0.0382%
$2.62$42,423+71.21%
2023-03-14PurchaseChief Executive Officer
20,000
0.0475%
$2.67$53,400+69.29%
2023-03-14Purchasedirector
13,808
0.0328%
$2.67$36,867+69.29%
2022-12-01PurchaseChief Executive Officer
15,000
0.0341%
$2.61$39,150+54.15%
2022-11-30PurchaseChief Executive Officer
15,000
0.0341%
$2.41$36,150+66.60%
2022-08-26Purchase
9,291
0.0231%
$3.41$31,682-5.78%
2022-08-24Purchase
8,244
0.0207%
$3.34$27,535-2.82%
2022-08-22Purchase
4,918
0.0118%
$3.16$15,541-2.21%
2022-08-18Purchase
1,151
0.0028%
$3.19$3,672-2.52%
2022-08-17PurchaseChief Executive Officer
40,000
0.0961%
$3.19$127,600-2.82%
2022-06-15PurchaseChief Executive Officer
30,000
0.0734%
$3.71$111,300-15.53%
2022-05-06PurchaseChief Executive Officer
10,000
0.0219%
$3.40$34,000-17.55%
2021-08-23SaleChief Executive Officer
48,175
0.1175%
$8.02$386,364-26.02%
2021-05-21SaleChief Executive Officer
24,312
0.0605%
$7.14$173,588-2.52%
2021-05-20SaleChief Executive Officer
14,876
0.0372%
$7.03$104,578-0.43%
2021-05-18SaleChief Executive Officer
39,188
0.0988%
$7.41$290,383-4.37%

Insider Historical Profitability

15.47%
Green James WChief Executive Officer
3111091
7.1328%
$2.25165+24.69%
Skystone Advisors LLC10 percent owner
3744819
8.5858%
$2.25645+9.98%
GRAZIANO CHANE10 percent owner
3105150
7.1192%
$2.2550+21.41%
HSO LIMITED PARTNERSHIP10 percent owner
2757257
6.3216%
$2.25402+8.24%
GREEN DAVIDdirector
925571
2.1221%
$2.251573+46.82%
Duchemin JeffreyChief Executive Officer
830888
1.905%
$2.25412+3.29%
LEWIS EARL Rdirector
467350
1.0715%
$2.2591+28.78%
LOY BERTRAND
399651
0.9163%
$2.25110+3.36%
Gagnon Robert E.Chief Financial Officer
321169
0.7363%
$2.25612+16.32%
EDRICK ALAN Idirector
202485
0.4642%
$2.2530+66.06%
KENNEDY JOHN Fdirector
177330
0.4066%
$2.2520<0.0001%
UVEGES GEORGEdirector
142685
0.3271%
$2.2552+13.68%
Eade Katherine A.director
121515
0.2786%
$2.2510+15.32%
Loewald Thomas Wdirector
103200
0.2366%
$2.2510+15.6%
HARTE NEAL Jdirector
25258
0.0579%
$2.2501

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
B Riley Asset Management Llc$12.02M6.532.83M-3.55%-$442,388.894.94
BlackRock$12.01M6.532.83M-2.75%-$339,836.02<0.0001
Punch & Associates Investment Management, Inc.$11.75M6.382.77M-4.99%-$617,746.780.68
Harvey Partners$10.84M5.892.56M0%+$01.21
Amh Equity Ltd$9.85M5.352.32M+7.46%+$683,941.6812.77
The Vanguard Group$9.13M4.962.15M+2.36%+$210,202.26<0.0001
Dimensional Fund Advisors$8.17M4.441.93M+0.04%+$2,929.84<0.01
Granahan Investment Management$7.9M4.291.86M+1.1%+$85,927.840.28
ROYCE & ASSOCIATES INC$5.72M3.111.35M-7.03%-$432,692.000.05
Boothbay Fund Management LLC$5.7M3.11.34M-1.3%-$75,094.640.18
Acadian Asset Management$4.25M2.311M-0.57%-$24,379.130.02
Heartland Advisors Inc$3.77M2.05889,133+2.62%+$96,103.840.03
Geode Capital Management$3.63M1.97856,224+6.41%+$218,758.92<0.0001
Meros Investment Management Lp$3.48M1.89821,792+0.25%+$8,658.081.56
Renaissance Technologies$2.98M1.62702,478-2.48%-$75,908.570.01
Portolan Capital Management$2.96M1.61697,840+3.82%+$108,840.820.23
State Street$2.94M1.6693,229+1.58%+$45,817.44<0.0001
Northern Trust$1.93M1.05456,097-2.47%-$48,976.23<0.0001
Acuitas Investments, LLC$1.38M0.75326,5160%+$00.74
Kennedy Capital Management Inc$1.36M0.74321,523-1.46%-$20,190.890.03
Bard Associates, Inc.$1.24M0.67291,320+2.07%+$25,007.520.47
Archon Capital Management Llc$1.11M0.6260,858-6.62%-$78,440.010.02
BNY Mellon$1.03M0.56243,130-2.6%-$27,479.44<0.0001
Charles Schwab$974,263.000.53229,779-2.92%-$29,247.52<0.0001
Greenwood Capital$918,443.000.5216,614-1.81%-$16,913.350.12
Bridgeway Capital Management$782,280.000.43184,500-7.01%-$58,936.000.01
New York State Common Retirement Fund$756,000.000.41178,350+25.19%+$152,132.55<0.01
Pasadena Private Wealth Llc$731,336.000.4172,4850%+$00.18
GlobeFlex Capital$626,680.000.34147,802-6.28%-$42,022.610.06
Connor Clark & Lunn Investment Management Ltd$610,793.000.33144,055+1.81%+$10,879.84<0.01
Nuveen$593,596.000.32139,9990%+$0<0.0001
Ohio Strs$488,000.000.27115,200+9.92%+$44,055.56<0.01
ClariVest Asset Management LLC$470,805.000.26111,039+0.19%+$881.920.05
Riverwater Partners$395,155.000.2293,197+14.06%+$48,726.040.32
Two Sigma Advisers LP$373,781.000.288,156-16.25%-$72,503.91<0.01
Morgan Stanley$339,264.000.1880,015-26.98%-$125,355.75<0.0001
Assenagon Asset Management S.A.$328,528.000.1877,4830%+$0<0.01
Prudential Financial$308,926.000.1772,860-18.65%-$70,807.91<0.0001
Jacobs Levy Equity Management$273,802.000.1564,576-4.34%-$12,435.91<0.01
Winton Capital Management$271,534.000.1564,041-0.15%-$407.040.02
Invesco$243,075.000.1357,329+24.64%+$48,047.69<0.0001
Two Sigma$177,999.000.141,981-21.15%-$47,733.80<0.0001
UBS$172,692.000.0940,729-12.55%-$24,782.95<0.0001
Goldman Sachs$169,303.000.0939,930-0.85%-$1,458.56<0.0001
RhumbLine Advisers$162,135.000.0938,241+4.54%+$7,042.34<0.0001
Legato Capital Management Llc$148,519.000.0835,028+9.4%+$12,766.660.02
Barclays$121,000.000.0728,657-48.64%-$114,598.91<0.0001
Hillsdale Investment Management Inc.$111,936.000.0626,400New+$111,936.000.01
Advisor Group Holdings Inc$107,435.000.0625,340+25,240%+$107,011.03<0.0001
Deutsche Bank$96,519.000.0522,764+2.84%+$2,662.71<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.